Oct 30, 8:17 AM ET
Organon filed its quarterly report for the period ended September 30, 2026, and furnished supplemental non-GAAP figures in place of an earnings release, which it has suspended because of its pending merger with Sun Pharmaceutical Industries. GAAP net income rose to $164 million from $160 million, but adjusted net income, adjusted EPS and adjusted EBITDA all declined from a year earlier.
- Quarter GAAP diluted EPS was $0.60 versus $0.61 a year earlier; non-GAAP adjusted diluted EPS was $0.94 versus $1.01
- Adjusted EBITDA was $502 million versus $518 million, and adjusted EBITDA margin was 31.9% versus 32.3%
- Nine-month adjusted diluted EPS was $2.51 versus $3.03, while GAAP diluted EPS was $1.56 versus $1.50
- No earnings call was held; the company said the pending Sun Pharmaceutical merger led to the suspension of its customary earnings release and call
Read the filing on SEC.gov ↗
Jun 11, 4:15 PM ET
At its June 9, 2026 Annual Meeting, Organon stockholders approved an amended and restated 2021 Incentive Stock Plan that adds 8,000,000 shares available for issuance. Stockholders also elected all ten director nominees and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026, so the outcome is a routine annual meeting with an equity plan change that adds potential share issuance.
- The amended and restated 2021 Incentive Stock Plan was approved at the June 9, 2026 Annual Meeting and adds 8,000,000 shares for issuance.
- All ten director nominees were elected to serve until the 2027 annual meeting; Ramona Sequeira received the most For votes at 146,867,855.
- In a non-binding advisory vote, named executive officer compensation received 142,593,022 For votes and 7,311,933 Against votes.
- PricewaterhouseCoopers LLP was ratified for fiscal year 2026 with 196,889,135 For votes and 4,100,954 Against votes.
Read the filing on SEC.gov ↗
Apr 30, 7:48 AM ET
Organon reported first-quarter 2026 revenue of $1.460 billion, down 4% from $1.513 billion a year earlier and down 9% excluding foreign currency, while GAAP net income rose to $146 million from $87 million. Non-GAAP adjusted diluted EPS fell to $0.71 from $1.02, and the company will not provide financial guidance because of its pending all-cash merger into Sun Pharma, which is expected to close in early 2027.
- Revenue was $1.460 billion, down 4% as reported and down 9% excluding foreign currency, from $1.513 billion in Q1 2025.
- GAAP diluted EPS was $0.55 versus $0.33; non-GAAP adjusted diluted EPS was $0.71 versus $1.02.
- Board declared a quarterly dividend of $0.02 per share, payable June 11, 2026, to holders of record on May 11, 2026.
- No financial guidance or earnings call due to the pending Sun Pharma merger, expected to close in early 2027 subject to regulatory and stockholder approval.
Read the filing on SEC.gov ↗
Apr 27, 6:06 AM ET
Organon agreed on April 26, 2026 to be acquired by Sun Pharma entities in an all-cash merger valued at an enterprise value of $11.75 billion. The $14.00 per share price represents a 103% premium to the closing share price on April 9, 2026, and the deal requires Organon stockholder approval and regulatory clearances.
- Organon stockholders would receive $14.00 per share in cash, a 103% premium to the April 9, 2026 closing price
- Enterprise value of the deal is $11.75 billion; Sun Pharma plans to fund it with available cash and committed bank financing
- The transaction is expected to close in early 2027 and can be terminated if the merger is not completed by January 26, 2027
- If completed, Organon shares would be delisted from the New York Stock Exchange
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.